Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18740120 | 1.00 | PTGER4 (0.49) | PTGER4PTGER2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL20539536 | 0.95 | PTGER4 (0.51) | PTGER4PTGER2NR1H4 | |
| SCHEMBL18758569 | 0.95 | PTGER4 (0.51) | PTGER4PTGER2NR1H4 | |
| SCHEMBL18758538 | 0.91 | PDE2A (0.43) | PTGER4PTGER2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18740241 | 0.87 | PTGER4 (0.51) | PTGER4PTGER2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18740243 | 0.87 | PTGER4 (0.51) | PTGER4PTGER2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18758566 | 0.86 | PTGER4 (0.42) | PTGER4PTGER2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL28922411 | 0.86 | PTGER4 (0.42) | PTGER4PTGER2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18740045 | 0.85 | PTGER4 (0.58) | PTGER4PTGER2 | |
| SCHEMBL18740042 | 0.85 | PTGER4 (0.58) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434246-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-09-06 | — | — | US | claimed |
| EP-3362454-B1 | EP4 ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2021-12-08 | — | — | EP | claimed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | claimed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | claimed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | claimed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | claimed |
| US-20180305362-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-25 | — | — | US | claimed |
| US-11434246-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-09-06 | — | — | US | disclosed |
| EP-3362454-B1 | EP4 ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| CN-108473497-B | EP4 antagonists | 卫材R&D 管理有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20180305362-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-25 | — | — | US | disclosed |
| EP-3362454-A1 | EP4 ANTAGONISTS | Eisai R&D Management Co., Ltd. (JP) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434246-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885CYP1A2 886/4885 |
| US-20180305362-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885CYP1A2 886/4885 |
| US-10316040-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885CYP1A2 886/4885 |
| US-10941148-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885CYP1A2 886/4885 |
| US-20190315754-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885CYP1A2 886/4885 |
| US-20210347779-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTGER4 1/4885PTGER2 4/4885CYP1A2 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.